Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Guangbing Xiong

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5109396853. Sources: OpenAlex.

Their work

Papers
17 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
36
Papers, trials and grants by year

2016: 1 paper · 2017: 3 papers · 2018: 3 papers · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 17

  1. The multifaceted roles of deubiquitinating enzymes (DUBs) in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-025-08052-7↗
  2. The ratio of skeletal muscle mass to body mass index combined with inflammatory immune markers to stratify survival of pancreatic cancer after pancreatoduodene… First author DOI 10.1016/j.ejso.2024.108355↗
  3. Using a microRNA panel of circulating exosomes for diagnosis of pancreatic cancer: multicentre case-control study. Co-author DOI 10.1093/bjs/znac375↗
  4. Targeting the alterations of ARID1A in pancreatic cancer: tumorigenesis, prediction of treatment, and prognostic value. First author PMID 36247295↗
  5. Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models. Co-author DOI 10.1158/1078-0432.ccr-19-3975↗
  6. Correction to: MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-021-02152-w↗
  7. Long Noncoding Competing Endogenous RNA Networks in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.765216↗
  8. OLR1 Promotes Pancreatic Cancer Metastasis via Increased c-Myc Expression and Transcription of HMGA2. First author DOI 10.1158/1541-7786.mcr-19-0718↗
  9. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1186/s13045-019-0777-7↗
  10. [The long coding RNA GSTM3TV2 acts an oncogene to promote chemoresistance in pancreatic cancer]. Co-author DOI 10.3760/cma.j.issn.0529-5815.2019.09.009↗
  11. MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-018-0739-x↗
  12. LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer. First author DOI 10.1186/s13046-018-0947-4↗
  13. [The expression of KLK7 in pancreatic cancer and the effects on the biological behavior of pancreatic cancer cells]. Co-author DOI 10.3760/cma.j.issn.0529-5815.2018.05.013↗
  14. The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2017.02.020↗
  15. PD-1/PD-L1 and immunotherapy for pancreatic cancer. First author DOI 10.1016/j.canlet.2017.08.006↗
  16. MicroRNA-1285 inhibits malignant biological behaviors of human pancreatic cancer cells by negative regulation of YAP1. First author DOI 10.4149/neo_2017_306↗
  17. PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value. First author DOI 10.1186/s13046-016-0406-z↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Taiping Zhang · 11 shared papers, 2016–2023 · strength 1.04
  2. Yupei Zhao · 10 shared papers, 2016–2021 · strength 0.88
  3. Mengyu Feng · 9 shared papers, 2017–2021 · strength 0.82
  4. Gang Yang · 9 shared papers, 2017–2021 · strength 0.82
  5. Lei You · 9 shared papers, 2016–2021 · strength 0.77
  6. Zhe Cao · 6 shared papers, 2016–2023 · strength 0.57
  7. Renyi Qin · 3 shared papers, 2021–2025 · strength 0.57
  8. Fangyu Zhao · 5 shared papers, 2019–2023 · strength 0.56
  9. Jiangdong Qiu · 4 shared papers, 2018–2023 · strength 0.45
  10. Min Wang · 2 shared papers, 2021–2025 · strength 0.41
  11. Jikuan Jin · 2 shared papers, 2021–2024 · strength 0.38
  12. Yueze Liu · 3 shared papers, 2020–2023 · strength 0.37
  13. Min Zhou · 1 shared paper, 2025 · strength 0.28
  14. Jun Gong · 1 shared paper, 2025 · strength 0.28
  15. Hua Huang · 3 shared papers, 2016–2021 · strength 0.26
  16. Renyi Qin · 1 shared paper, 2024 · strength 0.26
  17. Ruichao Li · 1 shared paper, 2022 · strength 0.22
  18. Lin Yang · 1 shared paper, 2022 · strength 0.22
  19. Jun Zhao · 1 shared paper, 2022 · strength 0.22
  20. Gang Yang · 1 shared paper, 2023 · strength 0.16
  21. Lei Wang · 1 shared paper, 2023 · strength 0.16
  22. Jinxin Tao · 1 shared paper, 2023 · strength 0.16
  23. Guangyu Chen · 1 shared paper, 2023 · strength 0.16
  24. Li Zhou · 2 shared papers, 2016–2019 · strength 0.14
  25. Jianwei Xu · 2 shared papers, 2016–2019 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.